Glyco-polypeptides in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans-A Double-Blind Study-Case Report of 126 Patients: Complete Study Report of Phase II Clinical Trial
Journal of Oncology Research and Therapy · 2021
DOI: 10.29011/2574-710x.010116 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Oncology Research and Therapy, 2021.
Abstract (Originalsprache)
Glyco-polypeptides (Comosain) induced leucocyte binding ability to tumor surface antigens, such as interleukin 2, 6, 8, and TNFs, is known as an immuno-target therapy. Using the different concentration of Bromelain proteinases.
Zitieren
APA
(2021). Glyco-polypeptides in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans-A Double-Blind Study-Case Report of 126 Patients: Complete Study Report of Phase II Clinical Trial. Journal of Oncology Research and Therapy. https://doi.org/10.29011/2574-710x.010116
Vancouver
Glyco-polypeptides in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans-A Double-Blind Study-Case Report of 126 Patients: Complete Study Report of Phase II Clinical Trial. Journal of Oncology Research and Therapy. 2021. doi:10.29011/2574-710x.010116
BibTeX
@article{euvimed2021,
title = {Glyco-polypeptides in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans-A Double-Blind Study-Case Report of 126 Patients: Complete Study Report of Phase II Clinical Trial},
journal = {Journal of Oncology Research and Therapy},
year = {2021},
doi = {10.29011/2574-710x.010116}
}
EUVIMED